ClariTrial | Search Clinical Trials

Explore/autoimmune immunology

Status

Phase

Pre-filtered to show active, later-stage trials with the strongest clinical signal.

41 results for “autoimmune immunology” · Recruiting · Phase 3 · Phase 2

Page 1 of 3

Recruiting

An Artificial Intelligence-powered Approach to Precision Immunotherapy of Human Arthritis

Phase 2Rheumatoid Arthritis (RA)Rheumatology

dnaJP1Placebo

Prof Salvatore Albani124 participants1 site · SingaporeCompletes Nov 2028

Compare CT.gov Full analysis →

Recruiting

Ublituximab in Autoantibody Positive Immune Mediated Necrotizing Myopathy

Phase 2Autoimmune Disorders

UblituximabPlacebo for Ublituximab

National Institute of Allergy and Infectious Diseases (NIAID)30 participants8 sites · United StatesCompletes Aug 2028

Compare CT.gov Full analysis →

Recruiting

Supporting Weak Immune System During Autoimmune Therapy: Testing Panzyga to Prevent Infections

Phase 3HypogammaglobulinemiaAutoimmune ConditionsRheumatic Conditions

Panzyga, 10% Intravenous SolutionPlacebo

Octapharma360 participants17 sites · United States, Bulgaria, GreeceCompletes Dec 2029

Compare CT.gov Full analysis →

Recruiting

Hematopoietic Stem Cell Transplantation (HSCT) for Common Variable Immunodeficiency (CVID) and Other Autoimmune Manifestations of Primary Immune Regulatory Disorders (PIRD)

Phase 2Common Variable Immunodeficiency (CVID)Primary Immune Regulatory DisorderImmune Dysregulation

Hematopoietic stem cell transplant (HSCT)

Paul Szabolcs25 participants1 site · United StatesCompletes May 2030

Compare CT.gov Full analysis →

Recruiting

Reduced Intensity Conditioning for Non-Malignant Disorders Undergoing UCBT, BMT or PBSCT

Phase 2Primary Immunodeficiency (PID)Congenital Bone Marrow Failure SyndromesInherited Metabolic Disorders (IMD)

HydroxyureaAlemtuzumabFludarabine+2 more

Paul Szabolcs100 participants1 site · United StatesCompletes Nov 2026

Compare CT.gov Full analysis →

Recruiting

Exploratory Study of Anti-BCMA-CD19 CAR-T Cell Therapy in Relapsed or Refractory IgG4-Related Disease

Phase 2IgG4 Related DiseaseB-cell Mediated Autoimmune Disorders

Anti-BCMA-CD19 CAR-T cells

Chinese PLA General Hospital9 participants1 site · ChinaCompletes Sep 2027

Compare CT.gov Full analysis →

Recruiting

A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease

Phase 3Systemic Lupus Erythematosus (SLE)Cutaneous Lupus Erythematosus (CLE)

EnpatoranPlaceboStandard of care (SoC)

EMD Serono Research & Development Institute, Inc.202 participants60 sites · United States, Australia, BrazilCompletes May 2029

Compare CT.gov Full analysis →

Recruiting

Phase 1b/2 Study of IV Sarilumab in Adult With RA

Phase 1Phase 2Rheumatoid Arthritis

Sarilumab, SAR153191 SCSarilumab, SAR153191 IV

Sanofi140 participants12 sites · United StatesCompletes Oct 2028

Compare CT.gov Full analysis →

Recruiting

Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty

Phase 2Rheumatic Disease

MethotrexateSulfasalazineHydroxychloroquine+24 more

NYU Langone Health80 participants1 site · United StatesCompletes Jan 2028

Compare CT.gov Full analysis →

Recruiting

VIBRANT: VIB4920 for Active Lupus Nephritis

Phase 2Lupus Nephritis

VIB4920Placebo for VIB4920

National Institute of Allergy and Infectious Diseases (NIAID)74 participants17 sites · United StatesCompletes Jun 2028

Compare CT.gov Full analysis →

Recruiting

Immunosuppression and COVID-19 Boosters

Phase 3COVID-19

diphtheria and tetanus toxoids (adsorbed) vaccineCOVID-19 vaccine

Kirby Institute320 participants5 sites · AustraliaCompletes Dec 2026

Compare CT.gov Full analysis →

Recruiting

Open-Label Study of Dimethyl Fumarate in Adults With Type 1 Diabetes

Phase 2Phase 3Type 1 Diabetes Mellitus

Dimethyl Fumarate Enteric-coated CapsulesInsulin

Nanjing Medical University96 participants1 site · ChinaCompletes Dec 2028

Compare CT.gov Full analysis →

Recruiting

Autologous Gene Therapy for Artemis-Deficient SCID

Phase 1Phase 2Severe Combined Immunodeficiency

AProArt-CD34CliniMACS® CD34 Reagent System cell sorter deviceBusulfan

University of California, San Francisco24 participants1 site · United StatesCompletes Jun 2038

Compare CT.gov Full analysis →

Recruiting

MB-CART19.1 in Refractory SLE

Phase 1Phase 2SLE - Systemic Lupus Erythematosus

MB-CART19.1

Miltenyi Biomedicine GmbH29 participants3 sites · GermanyCompletes Sep 2027

Compare CT.gov Full analysis →

Recruiting

Randomized Stepped Wedge Study of Emapalumab in APECED Enteritis

Phase 2Autoimmune Polyendocrinopathy Candidiasis Ectodermal Dystrophy Enteritis

Emapalumab

National Institute of Allergy and Infectious Diseases (NIAID)30 participants1 site · United StatesCompletes Mar 2031

Compare CT.gov Full analysis →

1–15 of 41

Explore/autoimmune immunology

Status

Phase

Pre-filtered to show active, later-stage trials with the strongest clinical signal.

41 results for “autoimmune immunology” · Recruiting · Phase 3 · Phase 2

Page 1 of 3

Recruiting

An Artificial Intelligence-powered Approach to Precision Immunotherapy of Human Arthritis

Phase 2Rheumatoid Arthritis (RA)Rheumatology

dnaJP1Placebo

Prof Salvatore Albani124 participants1 site · SingaporeCompletes Nov 2028

Compare CT.gov Full analysis →

Recruiting

Ublituximab in Autoantibody Positive Immune Mediated Necrotizing Myopathy

Phase 2Autoimmune Disorders

UblituximabPlacebo for Ublituximab

National Institute of Allergy and Infectious Diseases (NIAID)30 participants8 sites · United StatesCompletes Aug 2028

Compare CT.gov Full analysis →

Recruiting

Supporting Weak Immune System During Autoimmune Therapy: Testing Panzyga to Prevent Infections

Phase 3HypogammaglobulinemiaAutoimmune ConditionsRheumatic Conditions

Panzyga, 10% Intravenous SolutionPlacebo

Octapharma360 participants17 sites · United States, Bulgaria, GreeceCompletes Dec 2029

Compare CT.gov Full analysis →

Recruiting

Hematopoietic Stem Cell Transplantation (HSCT) for Common Variable Immunodeficiency (CVID) and Other Autoimmune Manifestations of Primary Immune Regulatory Disorders (PIRD)

Phase 2Common Variable Immunodeficiency (CVID)Primary Immune Regulatory DisorderImmune Dysregulation

Hematopoietic stem cell transplant (HSCT)

Paul Szabolcs25 participants1 site · United StatesCompletes May 2030

Compare CT.gov Full analysis →

Recruiting

Reduced Intensity Conditioning for Non-Malignant Disorders Undergoing UCBT, BMT or PBSCT

Phase 2Primary Immunodeficiency (PID)Congenital Bone Marrow Failure SyndromesInherited Metabolic Disorders (IMD)

HydroxyureaAlemtuzumabFludarabine+2 more

Paul Szabolcs100 participants1 site · United StatesCompletes Nov 2026

Compare CT.gov Full analysis →

Recruiting

Exploratory Study of Anti-BCMA-CD19 CAR-T Cell Therapy in Relapsed or Refractory IgG4-Related Disease

Phase 2IgG4 Related DiseaseB-cell Mediated Autoimmune Disorders

Anti-BCMA-CD19 CAR-T cells

Chinese PLA General Hospital9 participants1 site · ChinaCompletes Sep 2027

Compare CT.gov Full analysis →

Recruiting

A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease

Phase 3Systemic Lupus Erythematosus (SLE)Cutaneous Lupus Erythematosus (CLE)

EnpatoranPlaceboStandard of care (SoC)

EMD Serono Research & Development Institute, Inc.202 participants60 sites · United States, Australia, BrazilCompletes May 2029

Compare CT.gov Full analysis →

Recruiting

Phase 1b/2 Study of IV Sarilumab in Adult With RA

Phase 1Phase 2Rheumatoid Arthritis

Sarilumab, SAR153191 SCSarilumab, SAR153191 IV

Sanofi140 participants12 sites · United StatesCompletes Oct 2028

Compare CT.gov Full analysis →

Recruiting

Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty

Phase 2Rheumatic Disease

MethotrexateSulfasalazineHydroxychloroquine+24 more

NYU Langone Health80 participants1 site · United StatesCompletes Jan 2028

Compare CT.gov Full analysis →

Recruiting

VIBRANT: VIB4920 for Active Lupus Nephritis

Phase 2Lupus Nephritis

VIB4920Placebo for VIB4920

National Institute of Allergy and Infectious Diseases (NIAID)74 participants17 sites · United StatesCompletes Jun 2028

Compare CT.gov Full analysis →

Recruiting

Immunosuppression and COVID-19 Boosters

Phase 3COVID-19

diphtheria and tetanus toxoids (adsorbed) vaccineCOVID-19 vaccine

Kirby Institute320 participants5 sites · AustraliaCompletes Dec 2026

Compare CT.gov Full analysis →

Recruiting

Open-Label Study of Dimethyl Fumarate in Adults With Type 1 Diabetes

Phase 2Phase 3Type 1 Diabetes Mellitus

Dimethyl Fumarate Enteric-coated CapsulesInsulin

Nanjing Medical University96 participants1 site · ChinaCompletes Dec 2028

Compare CT.gov Full analysis →

Recruiting

Autologous Gene Therapy for Artemis-Deficient SCID

Phase 1Phase 2Severe Combined Immunodeficiency

AProArt-CD34CliniMACS® CD34 Reagent System cell sorter deviceBusulfan

University of California, San Francisco24 participants1 site · United StatesCompletes Jun 2038

Compare CT.gov Full analysis →

Recruiting

MB-CART19.1 in Refractory SLE

Phase 1Phase 2SLE - Systemic Lupus Erythematosus

MB-CART19.1

Miltenyi Biomedicine GmbH29 participants3 sites · GermanyCompletes Sep 2027

Compare CT.gov Full analysis →

Recruiting

Randomized Stepped Wedge Study of Emapalumab in APECED Enteritis

Phase 2Autoimmune Polyendocrinopathy Candidiasis Ectodermal Dystrophy Enteritis

Emapalumab

National Institute of Allergy and Infectious Diseases (NIAID)30 participants1 site · United StatesCompletes Mar 2031

Compare CT.gov Full analysis →

1–15 of 41